ClinicalTrials.gg
TerminatedNCT02257125Updated Aug 13, 2020

ArmeoSenso - Reward

An interventional study of high incentive and low incentive in Stroke, sponsored by Cereneo AG. Terminated at 3 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-13.

Sponsored by Cereneo AG · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Stopped due to futility considerations: Sample size calculations have assumed smaller effect sizes than considered relevant now.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 216 studies in Stroke with a site in Switzerland — 46 open to participants now, 60 under way, 6 of them phase 3. Stroke · Switzerland.

Enrollment
99th of 147
38 · median 79
Started
2015
with 11 others
No phase
95 of 216
24 open now
Registered
63rd of 216
by date
Lead sponsor
6 of 216
Cereneo AG

Among the 216 studies in Stroke with a site in Switzerland, this one is the 99th largest by enrollment of the 147 interventional ones that give a count, is one of 12 that started in 2015, is one of 95 with no phase, and was the 63rd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

46 of the 216 studies in Stroke with a site in Switzerland are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Stroke with a site in Switzerland, or all of them as a file.
02

Study summary

This study investigates the use of motivating/rewarding features in a computer based arm rehabilitation program. Half of the subjects will take part, besides receiving standard therapy, in a computer based program delivering a game like scenario with visual effects and monetary rewards in case of successful level completion, while the other half will take part in a similar program without visual effects or the possibility to earn money.

Read the detailed description

Rewards not only increase motivation to train, but have also been shown to influence motor skill learning via activation of dopaminergic brain structures. In goal oriented tasks, receiving information about goal achievement has a rewarding value, which is further increased if performance has monetary consequences. Computer games often strengthen this kind of information by presenting explosions and other salient stimuli when a goal is achieved (e.g. a target has been reached). The current study investigates the outcome of an arm rehabilitation program, based on such a computer game delivered in two versions. Stroke patients are asked to use their impaired arms to perform goal oriented movements. Movements are translated into movements of a virtual arm on a computer screen. Goals are "meteors", threatening to destroy a planet on which they fall, if not caught by the virtual arm. One version of the computer game delivers state of the art graphics including a number of visual effects and, if the planet was protected successfully, information about a monetary reward, whereas the other version of the program delivers schematic graphic objects only. Training time and intensity are kept constant and outcome measures, including standard clinical motor assessments, are compared between the groups.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • rehabilitation
  • virtual reality
  • stroke
  • upper extremity
  • arm
  • feedback
  • reward
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • stroke survivor (max. 100 days post-stroke)
  • upper extremity motor deficits
  • patient can lift the paretic arm against gravity
  • patient can move the hand at least 20x20 cm in a horizontal plane
  • patient is able and willing to participate
  • patient has signed

Exclusion criteria

Exclusion Criteria:

  • severe aphasia (impairing verbal instructions)
  • severe dementia (impairing the capability to understand instructions)
  • severe depression (impairing motivation to train)
  • relevant (in the judgement of the investigator) impairment of visual perception, (impairing perception of goals and feedback on the computer screen)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    high incentive

    game version including visual effects and monetary rewards

    Behavioral: high incentive

  • Active comparator
    low incentive

    game version without visual effects or monetary rewards

    Behavioral: low incentive

Interventions

  • Behavioralhigh incentive

    Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game includes visual effects and monetary rewards.

  • Behaviorallow incentive

    Subjects are required to use their arms in order to control a virtual "hand" on a computer screen to prevent objects from reaching the bottom. The game does not include visual effects or monetary rewards.

06

What researchers measure

Primary outcomes

  1. Change in ArmeoSenso - hand workspace

    The subject moves the affected arm as far as possible in all directions while sitting in a gaming position. Movement range is recorded.

    Time frame: Assessed for each training visit (i.e., 15 visits over 3 weeks between day 2 and day 22): Main outcome is the change in hand workspace over the training intervention.

Secondary outcomes

  1. Motivation questionnaire

    Measures motivation to train.

    Time frame: Assessed for each training visit (i.e., 15 visits over 3 weeks between day 2 and day 22)

  2. Wolf Motor Function Test

    Quantifies upper extremity motor ability through timed and functional tasks.

    Time frame: Baseline (day 1), post-training (day 23 ± 5 days) and 3 months post-training (day 113 ± 7 days); training lasts for 3 weeks (15 visits, one per workday)

  3. Fugl-Meyer Assessment Upper Extremity

    Measures motor impairment.

    Time frame: Baseline (day 1), post-training (day 23 ± 5 days) and 3 months post-training (day 113 ± 7 days); training lasts for 3 weeks (15 visits, one per workday)

  4. Box and Blocks Test

    Measures gross manual dexterity.

    Time frame: Baseline (day 1), post-training (day 23 ± 5 days) and 3 months post-training (day 113 ± 7 days); training lasts for 3 weeks (15 visits, one per workday)

  5. ArmeoSenso: pointing task

    Goal is to reach targets in the transversal plane in front of the subject: number of targets and time.

    Time frame: Assessed for each training visit (i.e., 15 visits over 3 weeks between day 2 and day 22)

  6. Motor Activity Log 14 (MAL-14)

    Self-reported movement ability.

    Time frame: Baseline (day 1), post-training (day 23 ± 5 days) and 3 months post-training (day 113 ± 7 days); training lasts for 3 weeks (15 visits, one per workday)

  7. Barthel Index

    Measure of independence in daily living.

    Time frame: Baseline (day 1), post-training (day 23 ± 5 days) and 3 months post-training (day 113 ± 7 days); training lasts for 3 weeks (15 visits, one per workday)

  8. NIHSS

    Measure of stroke severity.

    Time frame: Baseline (day 1), post-training (day 23 ± 5 days) and 3 months post-training (day 113 ± 7 days); training lasts for 3 weeks (15 visits, one per workday)

07

Study locations

3 sites
  • Cereneo, Center For Rehabilitation and Neurology
    Vitznau, Lucerne 6354, Switzerland
  • Klinik Adelheid
    Unterägeri, Zug 6314, Switzerland
  • Zuercher Reha Zentrum Wald
    Wald, Switzerland
08

References and documents

Publications

  • Widmer M, Held JPO, Wittmann F, Valladares B, Lambercy O, Sturzenegger C, Palla A, Lutz K, Luft AR. Reward During Arm Training Improves Impairment and Activity After Stroke: A Randomized Controlled Trial. Neurorehabil Neural Repair. 2022 Feb;36(2):140-150. doi: 10.1177/15459683211062898. Epub 2021 Dec 22. PubMed 34937456 ↗
  • Widmer M, Held JP, Wittmann F, Lambercy O, Lutz K, Luft AR. Does motivation matter in upper-limb rehabilitation after stroke? ArmeoSenso-Reward: study protocol for a randomized controlled trial. Trials. 2017 Dec 2;18(1):580. doi: 10.1186/s13063-017-2328-2. PubMed 29197412 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2015 to primary completion in Oct 2019, 57 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2014
First posted
Oct 6, 2014
StartActual
Jan 27, 2015
Primary completionActual
Oct 28, 2019
CompletionActual
Oct 28, 2019
Last update
Aug 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02257125
Lead sponsor
Cereneo AG
Responsible party
Sponsor
First posted
Oct 6, 2014
Start date
Jan 27, 2015
Primary completion
Oct 28, 2019
Completion
Oct 28, 2019
Last update
Aug 13, 2020

Study contacts

Andreas Luft, Prof.
principal investigator · University of Zurich, University Hospital Zurich

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion